Aberrant Expression and Modification of Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptors Involved in the Pathogenesis of Tumoral Cortisol Resistance

作者：Jiang, Jingjing; Li, Na; Wang, Xiaolin; Lu, Yan; Bi, Yufang; Wang, Weiqing; Li, Xiaoying; Ning, Guang^*

来源：Endocrinology, 2010, 151(8): 3697-3705.

DOI：10.1210/en.2010-0335

• GENERALIZED GLUCOCORTICOID RESISTANCE
• SUMO MODIFICATION
• GENE-EXPRESSION
• COREPRESSOR
• SMRT
• SUMOYLATION
• TRANSCRIPTION
• MUTATION
• CANCER
• CARCINOIDS

Ectopic ACTH syndrome (EAS) accounts for 10-15% of cases of Cushing's syndrome and is mostly caused by small cell lung cancers or thymic carcinoids. EAS is characterized by tumoral cortisol resistance, whose underlying mechanism remains unknown. In this study, we reported that silencing mediator of retinoic acid and thyroid hormone receptors (SMRT), a major nuclear corepressor, was aberrantly expressed in ACTH-secreting thymic carcinoids. Overexpression and knockdown of SMRT in the ACTH-secreting AtT-20 cell line demonstrated that SMRT participated in the negative feedback of dexamethasone-mediated suppression of proopiomelanocortin. Posttranslational modification by the small ubiquitin-like modifiers (SUMO), i.e. SUMOylation plays an important role in fine-tuning transcriptional activities. SUMOylation of SMRT was observed in dexamethasone-resistant cell lines. Moreover, overexpression of the deSUMOylation enzyme enhanced the suppression of proopiomelanocortin by dexamethasone in AtT-20 cells. An evolutionarily conserved consensus SUMOylation site was identified close to the histone deacetylase 3 recruiting domain of SMRT, which might interfere with the recruiting process. These results suggested that aberrant expression and modification of SMRT might be involved in the pathogenesis of tumoral cortisol resistance. A therapeutic approach targeting SMRT SUMOylation might be developed for EAS patients. (Endocrinology 151: 3697-3705, 2010)

• 出版日期2010-8
• 单位上海交通大学; 上海大学; 上海市闵行区中心医院